Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label previous answer version answering member constituency answering member printed answering member
tabling member	label

Search

1503384

	registered interest
	date	02/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Evusheld
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will publish (a) the full clinical and scientific advice that his Department received on Evusheld and (b) his Department's reasoning for its decision not to procure the drug for treatment of long covid-19.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	45044
	answer	answer is ministerial correction date of answer 27/09/2022 answer text <p>The Government has decided not to procure Evusheld for prevention through emergency routes at this time. This is a decision based on independent clinical advice by the multi-agency initiative, RAPID C-19 and a national expert policy working group. These groups considered a range of evidence, including clinical trial data, in vitro analysis and emerging observational studies and concluded there is currently insufficient evidence of benefit to recommend deployment. The Chief Medical Officer for England is content that the correct process for providing clinical advice has been followed and agree that this should now be referred to the National Institute for Health and Care Excellence for further evaluation.</p><p>The Department wrote to patient groups on 5 September 2022 with information on this decision and evidence considered. The letter summarised the evidence considered by RAPID C-19 which contributed to the decision not to procure and deploy Evusheld and detailed the next steps the Government will take. The Department intends to publish further details of the clinical advice received shortly.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 27/09/2022 15:02:05 answering member 4320 label Biography information for Robert Jenrick previous answer version 17526 answering member constituency Erewash answering member printed Maggie Throup answering member 4447
	tabling member	1506 label Biography information for Andrew Gwynne

1504790

	registered interest
	date	05/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the level of access to antiviral treatments for people who are acutely vulnerable to covid-19.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	47395
	answer	answer is ministerial correction date of answer 27/09/2022 answer text <p>For patients whose immune system means they are at the highest risk from COVID-19 and who test positive for the virus, treatments can be accessed directly through COVID Medicine Delivery Units (CMDUs). Those patients at high risk of COVID-19 who are ineligible to access treatments via CMDUs can access antivirals via the PANORAMIC national study.</p><p>The Department and NHS England are monitoring the uptake of antiviral treatment against those digitally identified as eligible. In England, 95% of eligible non-hospitalised patients who have received an antiviral treatment to date were treated within five days from the date of symptom onset.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 27/09/2022 15:24:35 answering member 4320 label Biography information for Robert Jenrick previous answer version 17717 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
	tabling member	1506 label Biography information for Andrew Gwynne

1504818

	registered interest
	date	05/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help evaluate future effectiveness of prophylactic covid-19 treatments.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	47397
	answer	answer is ministerial correction date of answer 27/09/2022 answer text <p>RAPID C-19 has enabled active multi-agency oversight of national and international trial evidence for COVID-19 therapies for potential treatment and prophylactic indications. To date, evidence has strongly supported treatment use, although emerging evidence on prophylactic use is continuing to be reviewed.</p><p>We are monitoring a range of treatment products through the Protect-V study, including sotrovimab and niclosamide, as administered over a six-month period in vulnerable renal and immunosuppressed patients, to assess their effectiveness and suitability. Where material evidence is identified, the formation and implementation of United Kingdom-wide clinical access policies will follow as previously for other treatments.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 27/09/2022 15:27:13 answering member 4320 label Biography information for Robert Jenrick previous answer version 17719 answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey answering member 4098
	tabling member	1506 label Biography information for Andrew Gwynne

1505926

	registered interest
	date	07/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Paxlovid
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many doses of Paxlovid procured by the Government are due to reach their expiry date in the next two months.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	49096
	answer	answer is ministerial correction date of answer 27/09/2022 answer text <p>No doses are due to reach the expiry date in the next two months.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 27/09/2022 12:01:16 answering member 4320 label Biography information for Robert Jenrick
	tabling member	1506 label Biography information for Andrew Gwynne

1505927

	registered interest
	date	07/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Evusheld
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether it remains her Department's policy to not procure Evusheld.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	49097
	answer	answer is ministerial correction date of answer 27/09/2022 answer text <p>The Government has decided not to procure Evusheld for prevention through emergency routes at this time. This is a decision based on independent clinical advice by the multi- agency initiative, RAPID C-19 and a national expert policy working group. These groups considered a range of evidence, including clinical trial data, in vitro analysis and emerging observational studies and concluded there is currently insufficient evidence of benefit to recommend deployment. The Chief Medical Officer for England is content that the correct process for providing clinical advice has been followed and agree that this should now be referred to the National Institute for Health and Care Excellence for further evaluation. The Department intends to publish further details of the clinical advice received shortly.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 27/09/2022 13:33:36 answering member 4320 label Biography information for Robert Jenrick
	tabling member	1506 label Biography information for Andrew Gwynne

1505930

	registered interest
	date	07/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Disease Control
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will meet with (a) clinically vulnerable, (b) clinically extremely vulnerable and (c) immunosuppressed patient access groups to discuss future covid-19 protections.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	49100
	answer	answer is ministerial correction date of answer 27/09/2022 answer text <p>Ministers and officials regularly engage with charities and organisations representing and supporting immunocompromised and immunosuppressed groups. This engagement continues and a forum is planned shortly to hear stakeholder’s concerns and progress on the enhanced protection programme.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 27/09/2022 11:36:14 answering member 4320 label Biography information for Robert Jenrick
	tabling member	1506 label Biography information for Andrew Gwynne

1506242

	registered interest
	date	08/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services: Weather
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she will take to protect the NHS from additional pressure over the winter months.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	49597
	answer	answer is ministerial correction date of answer 23/09/2022 answer text <p>The National Health Service is planning to substantially increase capacity and resilience in to protect the NHS from additional pressure during the winter. Bed capacity will be increased by the equivalent of at least 7,000 general and acute beds, including new physical beds and expanding the use of innovative virtual wards to treat patients safely at home.</p><p>This is in addition to an integrated COVID-19 booster and flu vaccination programme to reduce admissions caused by these viruses. The National Discharge Taskforce aims to reduce delayed discharge across acute, mental health and community care settings by working with social care partners to implement best practice, increase bed capacity and improve patient flow through hospitals.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 23/09/2022 08:18:15 answering member 4320 label Biography information for Robert Jenrick
	tabling member	1506 label Biography information for Andrew Gwynne

1506263

	registered interest
	date	08/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Immunosuppression
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, which Minister in her Department will have responsibility for (a) clinically vulnerable, (b) clinically extremely vulnerable and (c) immunosuppressed people.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	49601
	answer	answer is ministerial correction date of answer 27/09/2022 answer text <p>I have Ministerial portfolio responsibility for immunosuppressed people.</p><p>The success of the COVID-19 vaccination programme means the requirement for shielding and identifying people as clinically extremely vulnerable (CEV) is no longer necessary. However, there remains a smaller number of people whose immune system means they are at higher risk of serious illness from COVID-19, despite vaccination.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 27/09/2022 11:41:22 answering member 4320 label Biography information for Robert Jenrick
	tabling member	1506 label Biography information for Andrew Gwynne

1519504

	registered interest
	date	10/10/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Immunosuppression: Patients
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many meetings her Department has had with (a) clinically vulnerable, (b) clinically extremely vulnerable and (c) immunosuppressed patient support groups and charities since her appointment.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	59517
	answer	answer is ministerial correction date of answer 13/10/2022 answer text <p>The COVID-19 vaccination programme has ensured that identifying individuals as clinically vulnerable or clinically extremely vulnerable is no longer necessary. However, there remains a smaller number of people whose immune system means they are at higher risk of serious illness from COVID-19, despite vaccination.</p><p>The Enhanced Protection Programme stakeholder forum was held on 23 September 2022. The forum was chaired by Professor Dame Jenny Harries, the Chief Executive of UK Health Security Agency and attended by officials and charities and groups representing immunosuppressed patients. In addition, officials meet with individual charities representing these patients.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 13/10/2022 14:41:57 answering member 4320 label Biography information for Robert Jenrick
	tabling member	1506 label Biography information for Andrew Gwynne

1519993

	registered interest
	date	10/10/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Hospitals: Construction
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether her Department is committed to building 40 new hospitals by 2030.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	59528
	answer	answer is ministerial correction date of answer 24/10/2022 answer text <p>The Government is committed to building 40 new hospitals by 2030. Six are currently under construction and one is now completed.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 24/10/2022 08:27:18 answering member 4320 label Biography information for Robert Jenrick
	tabling member	1506 label Biography information for Andrew Gwynne